Mediwound in brief
Mediwound is a listed company in the Biotechnology industry, based in Israel. Its last known market value was $88 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $17 M and a net loss of $24 M. Its largest business segments by sales in 2025 were USA (69%), Spain (8%) and Italy (6%). Its shares trade under the symbol M8W.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Mediwound timeline
- 2014
- 🔔· approximateInitial public offering on Frankfurt
Events of Mediwound from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #220 (Jan 2020) · #222 (Jan 2021) · #313 (Jan 2022) · #272 (Dec 2022) · #266 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -140.8%
- Operating margin
- -149.0%
- Return on equity
- -54.7%
- Liabilities / assets
- 49.4%
- Revenue growth
- -16.1%
- R&D / revenue
- 84.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $17M | -16.1% | $-25M | $-24M | -140.8% |
| Dec 2024 | $20M | +8.2% | $-19M | $-30M | -149.5% |
| Dec 2023 | $19M | -29.5% | $-15M | $-7M | -36.0% |
| Dec 2022 | $27M | +11.5% | $-8M | $-20M | -74.0% |
| Dec 2021 | $24M | +9.2% | $-11M | $-14M | -57.0% |
| Dec 2020 | $22M | -31.6% | $-9M | $-9M | -42.3% |
| Dec 2019 | $32M | +835.0% | $4M | $5M | 15.6% |
| Dec 2018 | $3M | — | $-4M | $-1M | -31.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-16M | $6M | $-22M | $-2.10 | — |
| Dec 2024 | $-14M | $6M | $-20M | $-3.03 | — |
| Dec 2023 | $-10M | $6M | $-17M | $-0.75 | — |
| Dec 2022 | $-12M | $1M | $-12M | $-3.93 | — |
| Dec 2021 | $-9M | $0M | $-9M | $-3.48 | — |
| Dec 2020 | $-7M | $1M | $-8M | $-2.38 | — |
| Dec 2019 | $8M | $1M | $7M | — | — |
| Dec 2018 | $-12M | $1M | $-13M | — | — |
SEC filings
- Nov 12, 20266-KReport of foreign issuer
- Nov 5, 20266-KReport of foreign issuer
- Aug 13, 20266-KReport of foreign issuer
- May 27, 20266-KReport of foreign issuer
- May 6, 20266-KReport of foreign issuer
- Apr 2, 20266-KReport of foreign issuer
- Mar 30, 20266-KReport of foreign issuer
- Mar 5, 202620-FAnnual report (foreign issuer) · period to Dec 2025
- Mar 5, 20266-KReport of foreign issuer
- Feb 19, 20266-KReport of foreign issuer
- Jan 15, 20266-KReport of foreign issuer
- Jan 12, 20266-KReport of foreign issuer
Official filings of Mediwound with the US Securities and Exchange Commission.
Annual results
- Revenue
- $17 M
- Operating income
- $-25 M
- Net income
- $-24 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $86 M
- Total liabilities
- $43 M
- Total equity
- $44 M
As of December-2025
Mutual funds holding Mediwound#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 246,170 | $4 M | — | 0.02% | −0.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 240,677 | $4 M | — | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 157,100 | $2 M | — | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC | 146,717 | $2 M | — | 1.5% | +16% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 110,220 | $2 M | — | <0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 91,113 | $1 M | — | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 50,344 | $1 M | — | <0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc. | 40,939 | $1 M | — | 0.03% | +6.4% | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 34,168 | $1 M | — | 0.03% | +39% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 24,270 | $0 M | — | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 21,075 | $0 M | — | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC | 20,500 | $0 M | — | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 19,343 | $0 M | — | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 13,088 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc. | 12,300 | $0 M | — | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 10,799 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 9,255 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 9,041 | $0 M | — | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 8,462 | $0 M | — | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 6,967 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,369 | $0 M | — | <0.01% | +2.6% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 5,200 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 4,895 | $0 M | — | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 4,505 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 3,800 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 3,250 | $0 M | — | <0.01% | +51% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,350 | $0 M | — | <0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,328 | $0 M | — | 0.02% | +30% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 2,297 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,902 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,759 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,707 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 1,337 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 1,218 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,176 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 1,124 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 981 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 964 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 837 | $0 M | — | <0.01% | +23% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 785 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 714 | $0 M | — | <0.01% | −11% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 728 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 639 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 629 | $0 M | — | <0.01% | +2.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 610 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 471 | $0 M | — | <0.01% | +4.4% | May 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 459 | $0 M | — | <0.01% | +8.3% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 414 | $0 M | — | <0.01% | −6.3% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 397 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 365 | $0 M | — | <0.01% | −39% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 359 | $0 M | — | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 306 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 198 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 51 | $0 M | — | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 33 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 55 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Mediwound#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ofer GonenChief Executive Officer | Exercise of in-the-money derivative | +8,168 | 13.47 | 110 Klocal | 66,019 | Form 4 |
| filed | David Morton FoxDirector | Exercise of in-the-money derivative | +6,534 | 13.47 | 88 Klocal | 28,817 | Form 4 |
| filed | Nachum ShamirDirector | Exercise of in-the-money derivative | +16,336 | 13.47 | 220 Klocal | 72,151 | Form 4 |
| filed | Samuel RubinsteinDirector | Sellindirect | -525 | 12.72 | 7 Klocal | 0 | Form 4 |
| filed | Samuel RubinsteinDirector | Buyindirect | +525 | 12.62 | 7 Klocal | 525 | Form 4 |
| filed | Shmuel HessCOO & Chief Commercial Officer | Sell | -1,979 | 12.72 | 25 Klocal | 0 | Form 4 |
| filed | Shmuel HessCOO & Chief Commercial Officer | Sell | -1,979 | 13.13 | 26 Klocal | 0 | Form 4 |
| filed | Shmuel HessCOO & Chief Commercial Officer | Sell | -1,865 | 13.00 | 24 Klocal | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: Mediwound#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 14,643 shares at $13.56
- : 25,615 shares at $12.55
- : 23 shares at $12.07
- : 4,139 shares at $12.00
- : 653 shares at $12.18
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Mediwound scorecard#
Passes 0 of the 12 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 6
- ✗Revenue grew in the newest year-16.1%Revenue down 16.1% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-13.8%-13.8% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-13.8%-13.8% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-2.10 vs -3.03Diluted EPS -2.10 in fiscal 2025 against -3.03 the year before (report's currency).
- ✗Net income higher than five years earlier-$24 M-$24 M in fiscal 2025 against -$9 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 5
- ✗Profitable in the newest year-$24 MNet income -$24 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-149.0%-149.0% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-63.9%-63.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-149.0%-149.0% in fiscal 2025 against -31.5% in 2022.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Mediwound's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -149.0% | -60.5% | |
| Net margin | -140.8% | -68.9% | |
| Return on equity | -63.9% | -61.0% | |
| Revenue growth, 3 years a year | -13.8% | 12.9% | |
| Revenue growth | -16.1% | 15.8% | |
| Free cash flow margin | -127.5% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Revenue fell 16.1% against the year before.
- Net loss of $24 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$22 million.
Mediwound: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 17−16.1%100% | 20+8.2%100% | 19−29.5%100% | 26+11.5%100% | 24+9.2%100% | 22−31.5%100% | 32+835%100% | 3.4+36.3%100% | 2.5+60.2%100% | 1.6—100% | |
| Cost of revenue | 14−22.1%80.8% | 18+16.4%87.0% | 15+13.3%80.9% | 13−11.1%50.3% | 15+5.4%63.1% | 14+20.0%65.3% | 12+467%37.3% | 2.1+32.3%61.4% | 1.6−26.9%63.2% | 2.2—139% | |
| Gross profit | 3.3+23.5%19.2% | 2.6−26.4%13.0% | 3.6−72.8%19.1% | 13+50.1%49.7% | 8.8+16.2%36.9% | 7.5−62.2%34.7% | 20+1419%62.7% | 1.3+43.0%38.6% | 0.9—36.8% | −0.6—−38.5% | |
| Research and development | 14+61.3%84.4% | 8.9+18.9%43.9% | 7.5−26.7%40.0% | 10−0.7%38.4% | 10+33.2%43.2% | 7.7+54.9%35.4% | 5.0+22.0%15.6% | 4.1−25.4%120% | 5.5−22.7%219% | 7.1—454% | |
| Selling, general and administrative | 8.4+3.0%49.8% | 8.2+21.2%40.6% | 6.8−2.2%36.2% | 6.9+9.0%26.1% | 6.3+16.3%26.7% | 5.5+4.1%25.1% | 5.2+38.0%16.5% | 3.8+0.5%112% | 3.8−7.4%151% | 4.1—262% | |
| Selling and marketing | 0.5+24.3%3.0% | 0.4+15.4%2.0% | 0.4−7.5%1.9% | 0.4−21.4%1.5% | 0.5+73.8%2.1% | 0.3+41.0%1.3% | 0.2+4.2%0.6% | 0.2−18.6%5.6% | 0.2r−0.2+113%9.5% | 0.1—7.1% | |
| Total costs and expenses | 29+29.4%168% | 22+16.8%109% | 19−12.3%101% | 22+7.6%81.2% | 20+22.0%84.1% | 16+6.1%75.3% | 15+193%48.6% | 5.3−63.9%155% | 15−25.3%585% | 20—1255% | |
| Operating income | −25—−149% | −19—−95.9% | −15—−81.8% | −8.3—−31.5% | −11—−47.2% | −8.8−297%−40.6% | 4.5—14.1% | −4.0—−116% | −14—−548% | −20—−1294% | |
| Interest and finance income | 1.9−9.2%11.0% | 2.0−12.5%10.1% | 2.3+767%12.5% | 0.3+2355%1.0% | 0.0−96.3%0.0% | 0.3−31.6%1.4% | 0.4+5.3%1.4% | 0.4+18.1%12.1% | 0.3−15.7%14.0% | 0.4—26.6% | |
| Interest expense and finance costs | 2.5−80.8%14.5% | 13+577%63.4% | 1.9−83.7%10.1% | 12+403%43.9% | 2.3+80.9%9.7% | 1.3−57.1%5.9% | 3.0+40.9%9.4% | 2.1+69.1%62.2% | 1.3+39.7%50.2% | 0.9—57.5% | |
| Income before tax | −24—−140% | −30—−149% | −6.5—−35.0% | −20—−73.7% | −14—−56.9% | −9.3−549%−42.6% | 2.1—6.5% | — | — | — | |
| Income tax | 0.2+177%1.0% | 0.1−67.0%0.3% | 0.2+137%1.0% | 0.1+189%0.3% | 0.0—0.1% | 0—0.0% | 0—0.0% | — | — | — | |
| Income from continuing operations | −24—−141% | −30—−149% | −6.7—−35.9% | −20—−74.0% | −14—−57.0% | −9.3−549%−42.6% | 2.1—6.5% | −5.7—−167% | −15—−582% | −19—−1212% | |
| Income from discontinued operations | — | — | — | 0—0.0% | 0−100%0.0% | 0.1−97.2%0.4% | 2.9−37.3%9.1% | 4.6—135% | −7.6—−305% | — | |
| Net income including minority interests | −24—−141% | −30—−149% | −6.7—−35.9% | −20—−74.0% | −14—−57.0% | −9.2−286%−42.3% | 5.0—15.6% | −1.1—−31.1% | −22—−887% | −19—−1212% | |
| Earnings per share, basic | -2.10—— | -3.03—— | -0.75—— | -3.93—— | -3.48—— | -2.38—— | — | — | — | — | |
| Earnings per share, diluted | -2.10—— | -3.03—— | -0.75—— | -3.93—— | -3.48—— | -2.38—— | — | — | — | — | |
| Shares, weighted average (basic) | 11+14.2%— | 10.0+10.5%— | 9.0+80.7%— | 5.0+28.1%— | 3.9—— | — | — | 27+16.2%— | 23+6.8%— | 22—— | |
| Shares, weighted average (diluted) | 11+14.2%— | 10.0+10.5%— | 9.0+80.7%— | 5.0+28.1%— | 3.9−85.7%— | 27+0.1%— | 27+0.2%— | 27+16.2%— | 23—— | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 4.8−47.6%5.6% | 9.2−22.8%12.5% | 12−65.0%17.9% | 34+207%67.8% | 11−36.4%55.9% | 17+140%55.9% | 7.2+7.8%17.8% | 6.7−81.4%19.0% | 36+25.0%81.7% | 29—80.7% | |
| Receivables | 1.6−66.2%1.9% | 4.8+29.7%6.5% | 3.7−60.4%5.6% | 9.3+425%18.7% | 1.8−35.7%9.0% | 2.8−32.6%8.9% | 4.1+633%10.1% | 0.6+51.8%1.6% | 0.4+11.1%0.8% | 0.3—0.9% | |
| Inventory | 4.1+52.0%4.7% | 2.7−5.4%3.7% | 2.8+45.0%4.3% | 2.0+63.6%3.9% | 1.2−13.0%6.1% | 1.4−14.4%4.4% | 1.6−4.0%4.0% | 1.7−10.9%4.8% | 1.9+123%4.3% | 0.8—2.4% | |
| Current assets | 60+15.0%69.5% | 52+5.0%71.0% | 50+8.4%74.8% | 46+207%91.7% | 15−42.9%75.7% | 26−26.5%84.3% | 36r36+8.9%87.8% | 33−21.2%92.7% | 42+23.5%94.1% | 34—94.0% | |
| Property, plant and equipment | 19+31.9%21.6% | 14+53.1%19.2% | 9.2+290%13.9% | 2.4−4.5%4.7% | 2.5−5.8%12.6% | 2.6+14.1%8.5% | 2.3+14.1%5.7% | 2.0+5.0%5.7% | 1.9+50.8%4.4% | 1.3—3.6% | |
| Right-of-use (leased) assets | 7.2+7.3%8.3% | 6.7−0.5%9.1% | 6.7+451%10.1% | 1.2−21.5%2.4% | 1.5−17.8%7.8% | 1.9−15.5%6.1% | 2.2—5.5% | — | — | — | |
| Other intangible assets | 0.0−66.7%0.0% | 0.1−40.0%0.1% | 0.2−28.6%0.2% | 0.2−22.2%0.5% | 0.3−18.2%1.5% | 0.4−15.4%1.2% | 0.4−13.3%1.1% | 0.5−22.0%1.4% | 0.6−17.9%1.4% | 0.8—2.2% | |
| Non-current assets | 26+23.2%30.5% | 21+27.3%29.0% | 17+301%25.2% | 4.2−12.9%8.3% | 4.8−1.7%24.3% | 4.9−1.7%15.7% | 5.0r5.0+93.6%12.2% | 2.6−2.0%7.3% | 2.6+21.5%5.9% | 2.2—6.0% | |
| Total assets | 86+17.4%100% | 73+10.6%100% | 66+32.9%100% | 50+153%100% | 20−36.5%100% | 31−23.5%100% | 41+15.1%100% | 35−20.1%100% | 44+23.4%100% | 36—100% | |
| Accounts payable | 7.6+44.8%8.9% | 5.3−4.5%7.2% | 5.5—8.3% | — | — | — | — | — | — | — | |
| Current liabilities | 26−3.1%29.8% | 27+46.4%36.1% | 18r11+50.3%27.3% | 12+12.5%24.1% | 11+29.7%54.3% | 8.3−20.3%26.6% | 10+112%25.6% | 4.9−9.9%13.9% | 5.4+1.0%12.3% | 5.4—15.0% | |
| Lease liabilities (non-current) | 8.2+25.2%9.5% | 6.5+2.6%8.9% | 6.4+651%9.6% | 0.8−39.2%1.7% | 1.4−20.1%7.0% | 1.7−13.2%5.6% | 2.0—4.9% | 0—0.0% | — | — | |
| Non-current liabilities | 17+7.0%19.6% | 16−5.6%21.5% | 17r24−38.1%25.2% | 27+98.8%54.1% | 14−12.4%68.9% | 16+3.2%50.0% | 15−29.7%37.1% | 21−26.4%60.7% | 29+28.6%65.9% | 23—63.2% | |
| Total liabilities | 43+0.7%49.4% | 42+21.5%57.6% | 35−10.8%52.5% | 39+60.7%78.2% | 24+2.2%123% | 24—76.6% | — | — | — | — | |
| Retained earnings | −229—−265% | −205—−279% | −175—−263% | −168—−336% | −149—−752% | −135—−434% | −126—−310% | −131—−371% | −129—−293% | −107—−300% | |
| Total equity | 44+40.1%50.6% | 31−1.4%42.4% | 32+189%47.5% | 11—21.8% | −4.6−163%−23.2% | 7.3−52.1%23.4% | 15+69.1%37.4% | 9.0−4.3%25.4% | 9.4r9.6+20.6%21.2% | 7.8—21.7% | |
| Total liabilities and equity | 86+17.4%100% | 73+10.6%100% | 66+32.9%100% | 50+153%100% | 20−36.5%100% | 31−23.5%100% | 41+15.1%100% | 35−20.1%100% | 44+23.4%100% | 36—100% | |
| Shares outstanding | 13+18.9%— | 11+17.0%— | 9.2+27.4%— | 7.2+85.8%— | 3.9r27−85.7%— | 27+0.1%— | 27+0.1%— | 27+0.5%— | 27+23.3%— | 22—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.9+25.4%11.0% | 1.5+13.8%7.3% | 1.3+2.4%7.0% | 1.3+2.7%4.8% | 1.2+13.6%5.2% | 1.1−5.1%5.0% | 1.1+99.1%3.6% | 0.6+1.8%17.0% | 0.6−3.7%22.7% | 0.6—37.8% | |
| Share-based compensation | 3.1−1.0%18.3% | 3.1+61.8%15.5% | 1.9−0.3%10.4% | 1.9+16.3%7.3% | 1.7+26.6%7.0% | 1.3+7.1%6.1% | 1.2+91.3%3.9% | 0.6−52.7%19.0% | 1.4−57.0%54.6% | 3.2—204% | |
| Cash from operating activities | −16—−95.1% | −14—−67.4% | −10—−56.0% | −12—−44.9% | −8.9—−37.5% | −6.9−183%−31.7% | 8.3—26.1% | −12—−357% | −16—−659% | −16—−1056% | |
| Capital expenditure | −5.5—−32.5% | −6.3—−31.0% | −6.5—−34.6% | −0.6—−2.1% | −0.5—−2.1% | −0.9—−4.2% | −0.8—−2.5% | −0.5—−15.3% | −1.0—−41.9% | −0.7—−43.1% | |
| Intangible assets bought | — | — | — | — | — | — | — | −0.0—−0.4% | −0.0—−1.2% | −0.0—−1.9% | |
| Cash from investing activities | −18—−106% | −8.4—−41.5% | −34—−184% | −0.5−114%−1.8% | 3.5−79.6%14.9% | 17—79.9% | −6.9—−21.7% | −17−3999%−501% | 0.4−75.9%17.5% | 1.8—117% | |
| Shares issued | — | — | — | 38—145% | 0—0.0% | 0—0.0% | — | — | 23—908% | — | |
| Cash from financing activities | 30+52.7%175% | 19−15.4%95.9% | 23−35.9%123% | 36—135% | −1.1—−4.4% | — | — | 0.0−99.8%1.4% | 23+2435%921% | 0.9—58.2% | |
| Exchange-rate effect on cash | 0.1—0.6% | −0.1—−0.4% | −0.2—−0.9% | −0.5−724%−2.1% | 0.1−67.8%0.4% | 0.3+95.0%1.3% | 0.1—0.4% | −0.2−191%−6.0% | 0.2+163%9.1% | 0.1—5.5% | |
| Change in cash | −4.4—−25.7% | −2.7—−13.4% | −22−196%−118% | 23—86.2% | −6.3−161%−26.6% | 10+207%47.5% | 3.4—10.6% | −29−435%−863% | 8.8—351% | −14—−875% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Mediwound sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- USA$12 M69%-24%
- Rest of the world$2 M12%-9.6%
- Spain$1 M7.6%+54%
- Italy$1 M5.9%+22%
- Germany$1 M4.8%+0.0%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2022 | $17 M | Private placement after listing | $10 to $50 million | 10 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Mediwound compares in Biotechnology
- Revenue$17 M · higher than 49% of 647
- Net margin-140.8% · higher than 37% of 408
- Revenue growth-16.1% · higher than 31% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Mediwound🇮🇱 | $88 M | — | -140.8% | -16.1% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Mediwound? Verify and update this profile — free
Show Mediwound's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.